When I first look at ACADIA Pharmaceuticals, I see a company that has already accomplished something many biotechnology businesses never manage to do: It has moved beyond the PowerPoint stage. ACADIA has actual products, actual revenue, and actual patients using its medicines. That may sound like a low bar until I remember how many biotechnology companies spend years discussing enormous addressable markets while producing little besides clinical-trial expenses and increasingly imaginative investor presentations. ACADIA is different. NUPLAZID has established the company in Parkinson’s disease psychosis, while DAYBUE has given it a commercial position in Rett syndrome. Those two products generated combined second-quarter 2026 revenue of approximately $308 million. Management raised its full-year revenue guidance to between $1.24 billion and $1.30 billion, including projected DAYBUE sales of $480 million to $510 million and NUPLAZID sales of $760 million to $790 million. ACADIA’s second-q...
When I look at ACADIA Pharmaceuticals, I see a company that has already crossed one of biotechnology’s most dangerous borders: it has stopped being a clinical-stage promise factory and become a commercial business. That distinction matters. ACADIA has two approved products, growing revenue, positive net income, and enough cash to fund a serious development program without immediately passing a collection plate among shareholders. It also has a pipeline capable of changing the company’s long-term value—assuming, as always, that biology agrees to cooperate. That last condition deserves emphasis. Biotechnology investors have a charming habit of treating every clinical program as an approved blockbuster temporarily inconvenienced by the absence of evidence. A compound enters Phase 2, management displays an enormous patient population, and somebody multiplies that population by the annual treatment cost. By lunchtime, the drug is supposedly worth $12 billion. Actual drug development is less...